“Nephrotic syndrome with sunitinib-associated focal segmental glomerulosclerosis in a patient with renal carcinoma: partial reversibility after dose adjustment: Case Report”., REV SEN, vol. 13, no. 2, pp. 149–156, Aug. 2025, doi: 10.56867/118.